SCHEMBL12426663

SCHEMBL12426663

COc1cc(C(=O)NCC2CN(C(=O)OC(C)(C)C)C2)ccc1N

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR4 Q13639 2/20 0.56
NAMPT P43490 2/20 0.53
KDM4E B2RXH2 1/20 0.51
PKM P14618 1/20 0.51
EGLN2 Q96KS0 1/20 0.49
PDE4B Q07343 3/20 0.44
PDE4A P27815 2/20 0.43
PDE4C Q08493 2/20 0.43
PDE4D Q08499 2/20 0.43
TDP1 Q9NUW8 1/20 0.42
ACKR3 P25106 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
MAPK14 Q16539 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC2 Q92769 1/20 0.41
POLB P06746 1/20 0.40
HRH1 P35367 1/20 0.40
CCR3 P51677 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13575607 0.92 HTR4 (0.60) HTR4NAMPTKDM4EPKMPDE4B
SCHEMBL12427424 0.84 USP30 (0.52) HTR4PDE4BPDE4APDE4CPDE4D
SCHEMBL30718473 0.81 KDM4E (0.61) NAMPTKDM4EPKMEGLN2ACKR3
SCHEMBL4802575 0.81 HTR4 (0.72) HTR4PDE4BPDE4APDE4CPDE4D
SCHEMBL12426363 0.80 HTR4 (0.66) HTR4TDP1POLBKCNH2F10
SCHEMBL30718491 0.80 KDM4E (0.62) NAMPTKDM4EPKMEGLN2ACKR3
SCHEMBL27307876 0.80 KDM4E (0.65) NAMPTKDM4EPKMEGLN2ACKR3
SCHEMBL15145007 0.79 KDM4E (0.61) NAMPTKDM4EPKMEGLN2ACKR3
SCHEMBL13175812 0.79 HTR4 (0.69) HTR4PDE4BPDE4APDE4CPDE4D
SCHEMBL13175546 0.79 HTR4 (0.69) HTR4PDE4BPDE4APDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8003785-B2 Halo-substituted pyrimidodiazepines TAKEDA PHARMACEUTICAL COMPANY LIMITED (US) 2011-08-23 US disclosed
US-20090318408-A1 HALO-SUBSTITUTED PYRIMIDODIAZEPINES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-12-24 US disclosed
WO-2009153197-A1 HALO-SUBSTITUTED PYRIMIDODIAZEPINES AS PLKL INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2009-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318408-A1 HALO-SUBSTITUTED PYRIMIDODIAZEPINES PLK1, CCNI, CDK1 HTR4 2822/4885NAMPT 2278/4885KDM4E 2536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.